Results 211 to 220 of about 400,239 (293)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

In vitro pharmacology of U-97018, a novel AT1 subtype angiotensin II receptor antagonist.

open access: diamond, 1994
Osamu Morita   +4 more
openalex   +1 more source

Polymorphism of the angiotensin I-Converting enzyme gene in diabetic nephropathy in Type II diabetic patients with proliferative retinopathy [PDF]

open access: bronze, 1998
Osamu Hanyu   +6 more
openalex   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié   +5 more
wiley   +1 more source

HSPD1 regulates angiotensin II‑induced atrial fibrillation via the PPAR signaling pathway. [PDF]

open access: yesMol Med Rep
Zhou Y   +8 more
europepmc   +1 more source

Dataset for "Co-Localization of Microstructural Damage and Excessive Mechanical Strain at Aortic Branches in Angiotensin-II Infused Mice"

open access: green, 2019
Lydia Aslanidou   +6 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Angiotensin II Activates Yes-Associated Protein (YAP) in Fibroblast Promoting Deep Fascia Remodeling. [PDF]

open access: yesInt J Mol Sci
Caroccia B   +12 more
europepmc   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy